MARKET

ORGS

ORGS

Orgenesis Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.09
-0.31
-5.74%
Closed 16:00 01/21 EST
OPEN
5.39
PREV CLOSE
5.40
HIGH
5.39
LOW
5.00
VOLUME
85.73K
TURNOVER
--
52 WEEK HIGH
5.93
52 WEEK LOW
2.350
MARKET CAP
82.26M
P/E (TTM)
-3.4581
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ORGS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ORGS News

  • Orgenesis Inc. Announces $9.2M Private Placement
  • Benzinga.9h ago
  • Orgenesis Inc. Announces $9.2 Million Private Placement
  • GlobeNewswire.9h ago
  • Orgenesis Appoints Industry Veteran Mario Philips to its Board of Directors
  • GlobeNewswire.01/13 14:25
  • Orgenesis Announces Addition of University of California, Davis, to its Point of Care Network; UC Davis Health to Utilize Orgenesis Point of Care Platform for the Development, Commercialization and Supply of Cell and Gene Therapy Products
  • GlobeNewswire.01/10 12:00

More

Industry

Biotechnology & Medical Research
-0.76%
Pharmaceuticals & Medical Research
-0.40%

Hot Stocks

Name
Price
%Change

About ORGS

Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.
More

Webull offers Orgenesis Inc (ORGS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.